GlobeNewswire Inc.··Cardiff Oncology, Inc.Cardiff Oncology Advances Onvansertib to Phase 3 After Positive RAS-Mutated Colorectal Cancer Data
Cardiff Oncology will present updated Phase 2 data for onvansertib in colorectal cancer at ASCO 2026, selecting the 30 mg dose for Phase 3 registration trials.
CRDFcolorectal cancerPhase 3 trial